Freedom of Information Request: 0893 2020/21
I’ve got a Freedom of Information query that I hope you’ll be able to help me with
Within the last 2 years, has the institution accepted or is it currently accepting any of the following drugs free of charge or for a nominal charge (eg £1):
Rizankizumab (Skyrizi) – Yes
Guselkumab (Tremfya) – No
Brodalumab (Kyntheum) – Yes
Ixekizumab (Taltz) – No
Secukinumab (Cosentyx) – out come scheme as opposed to a FOC scheme
Tildrakizumab (Ilumetri) – No
If yes to any of the above, are you able to say how long is the free of charge drug stock typically provided for each patient? For example, is it :
First 3 months
Some other period?
- Rizankizumab (Skyrizi) – Until May 2020.
- Brodalumab (Kyntheum) – first 3 months
If the Institution has not accepted manufacturer provision of free of charge drug stock, are you able to say what have been the reasons for this?
Generally, no interest from the clinical specialties.